Online citations, reference lists, and bibliographies.
← Back to Search

Zanamivir Amidoxime- And N-Hydroxyguanidine-Based Prodrug Approaches To Tackle Poor Oral Bioavailability.

D. Schade, J. Kotthaus, Lukas Riebling, Joscha Kotthaus, H. Müller-Fielitz, W. Raasch, A. Hoffmann, M. Schmidtke, B. Clement
Published 2015 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The neuraminidase (NA) inhibitor zanamivir (1) is potently active against a broad panel of influenza A and B strains, including mutant viruses, but suffers from pharmacokinetic (PK) shortcomings. Here, distinct prodrug approaches are described that aimed at overcoming zanamivir's lack of oral bioavailability. Lowering the high basicity of the 4-guanidino group in zanamivir and of a bioisosteric 4-acetamidine analog (5) by N-hydroxylation was deemed to be a plausible tactic. The carboxylic acid and glycerol side chain were also masked with different ester groups. The bioisosteric amidine 5 turned out to be potently active against a panel of H1N1 (IC50 = 2-10 nM) and H3N2 (IC50 = 5-10 nM) influenza A viruses (NA inhibition assay). In vitro PK studies showed that all prodrugs were highly soluble, exhibited low protein binding, and were bioactivated by N-reduction to the respective guanidines and amidines. The most promising prodrug candidates, amidoxime ester 7 and N-hydroxyguanidine ester 8, were subjected to in vivo bioavailability studies. Unfortunately, both prodrugs were not orally bioavailable to a convincing degree (F ≤ 3.7%, rats). This finding questions the general feasibility of improving the oral bioavailability of 1 by lipophilicity-increasing prodrug strategies, and suggests that intrinsic structural features represent key hurdles.
This paper references
10.1038/clpt.2010.187
The Role of Clinical Pharmacology in Supporting the Emergency Use Authorization of an Unapproved Anti‐Influenza Drug, Peramivir
V. Arya (2010)
10.1039/c0ob01117g
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
10.1371/journal.pone.0043491
Supply of Neuraminidase Inhibitors Related to Reduced Influenza A (H1N1) Mortality during the 2009–2010 H1N1 Pandemic: An Ecological Study
Paula E. Miller (2012)
10.1021/TX9502047
Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz.
B. Clement (1996)
10.1016/0006-2952(93)90616-5
Cytochrome P450 dependent N-hydroxylation of a guanidine (debrisoquine), microsomal catalysed reduction and further oxidation of the N-hydroxy-guanidine metabolite to the urea derivative. Similarity with the oxidation of arginine to citrulline and nitric oxide.
B. Clement (1993)
10.4155/fmc.10.292
Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode.
J. Kirchmair (2011)
10.1056/NEJMoa1304459
Human infection with a novel avian-origin influenza A (H7N9) virus.
Rongbao Gao (2013)
10.2217/FVL.14.97
Complementary assays helping to overcome challenges for identifying neuraminidase inhibitors
Martina Richter (2015)
10.1016/S0166-0934(01)00305-6
A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1.
M. Schmidtke (2001)
10.1128/AAC.00555-08
Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008
Tiffany G. Sheu (2008)
10.1038/nrd2175
Antiviral agents active against influenza A viruses
E. Clercq (2006)
10.3851/IMP2067
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
H. Nguyen (2012)
10.1128/AAC.01311-09
Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration
Shuku Kubo (2010)
10.1073/PNAS.100133697
A DNA transfection system for generation of influenza A virus from eight plasmids.
E. Hoffmann (2000)
10.1128/AAC.37.7.1473
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.
J. M. Woods (1993)
10.1038/nature08182
Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic
G. Smith (2009)
10.2165/00003088-199936001-00001
Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers
L. Cass (1999)
10.1124/dmd.105.004572
METABOLISM OF N-HYDROXYGUANIDINES (N-HYDROXYDEBRISOQUINE) IN HUMAN AND PORCINE HEPATOCYTES: REDUCTION AND FORMATION OF GLUCURONIDES
A. K. Froehlich (2005)
10.1345/aph.10118
Neuraminidase Inhibitors: Zanamivir and Oseltamivir
I. McNicholl (2001)
10.1021/mp300564v
Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
D. Gupta (2013)
10.1021/jm300455c
Antivirals targeting influenza A virus.
K. Das (2012)
10.1056/NEJMp0910479
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.
D. Birnkrant (2009)
10.1021/jm401492x
Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
D. Schade (2014)
10.1098/RSTB.2001.1021
Zanamivir: from drug design to the clinic.
M. Elliott (2001)
10.1126/SCIENCE.1090350
Are We Ready for Pandemic Influenza?
R. Webby (2003)
10.1021/JM0002679
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
Y. Babu (2000)
10.1056/NEJMoa0903810
Emergence of a novel swine-origin influenza A (H1N1) virus in humans.
Fatimah S. Dawood (2009)
10.1021/JO991458Q
A versatile one-Pot synthesis of 1,3-substituted guanidines from carbamoyl isothiocyanates
Linton (2000)
10.1016/S0040-4039(96)02268-X
S-2-Naphthylmethyl thioacetimidate hydrobromide: A new odorless reagent for the mild synthesis of substituted acetamidines
B. G. Shearer (1997)
10.1021/OL061454P
NG-hydroxyguanidines from primary amines.
N. Martin (2006)
10.1021/jm901440f
Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai.
U. Grienke (2010)
10.1016/j.antiviral.2009.01.006
Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Katja Bauer (2009)
10.1039/P19910002627
Stereoselective synthesis of 1,2-diols by the cycloadditive strategy: total synthesis of (±)-exo-brevicomin and (±)-and (–)-pestalotin
J. Zhang (1991)
10.1021/mp100050d
Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.
J. Miller (2010)
10.1021/mp200291x
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.
S. V. Gupta (2011)
10.3851/IMP1688
Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza
M. Yamashita (2010)
10.1093/jac/dkq015
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations
B. Davies (2010)
10.1016/j.bmc.2011.06.080
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
K. Liu (2011)
10.1021/JM980162U
Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors.
C. U. Kim (1998)



This paper is referenced by
10.3390/ijms21176002
Are Myths and Preconceptions Preventing Us from Applying Ionic Liquid Forms of Antiviral Medicines to the Current Health Crisis?
Julia L. Shamshina (2020)
The design, synthesis and biological evaluation of carbohydrate-based probes of proteins
Cindy J. Carroux (2017)
10.3390/molecules22101736
Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years
Hanadi Sinokrot (2017)
10.1016/j.bmcl.2019.06.045
Evaluation of amidoxime derivatives as prodrug candidates of potent bis-cationic antimalarials.
Olivier Berger (2019)
10.3389/fmicb.2017.00205
Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases
A. Hoffmann (2017)
10.1016/j.xphs.2015.11.036
Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue.
T. Incecayir (2016)
10.1055/a-1228-8473
High-performance Countercurrent Chromatography to Access Rhodiola rosea Influenza Virus Inhibiting Constituents.
J. Langeder (2020)
10.1021/acs.jmedchem.6b01115
Binding and Proton Blockage by Amantadine Variants of the Influenza M2WT and M2S31N Explained.
Christina Tzitzoglaki (2017)
10.1016/j.jviromet.2016.09.014
Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.
A. Hoffmann (2016)
10.1038/srep27156
Discovery of prenylated flavonoids with dual activity against influenza virus and Streptococcus pneumoniae
U. Grienke (2016)
10.1021/acsmedchemlett.6b00311
Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited.
Antonios Drakopoulos (2017)
10.1016/j.poly.2020.114590
Amantadine copper(II) chloride conjugate with possible implementation in influenza virus inhibition
C. N. Banti (2020)
10.1002/cmdc.202000349
A Novel Prodrug of a nNOS Inhibitor with Improved Pharmacokinetic Potential
C. Maccallini (2020)
Semantic Scholar Logo Some data provided by SemanticScholar